Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EBT (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of EBT data on record, last reported at $45.0 million in Q4 2025.

  • For Q4 2025, EBT rose 160.76% year-over-year to $45.0 million; the TTM value through Dec 2025 reached $108.6 million, up 10.19%, while the annual FY2025 figure was $108.6 million, 10.19% up from the prior year.
  • EBT reached $45.0 million in Q4 2025 per COLL's latest filing, up from $43.4 million in the prior quarter.
  • Across five years, EBT topped out at $46.7 million in Q4 2023 and bottomed at -$38.9 million in Q4 2021.
  • Average EBT over 5 years is $12.5 million, with a median of $15.5 million recorded in 2021.
  • The widest YoY moves for EBT: up 3338.67% in 2021, down 635.33% in 2021.
  • A 5-year view of EBT shows it stood at -$38.9 million in 2021, then surged by 79.96% to -$7.8 million in 2022, then soared by 699.54% to $46.7 million in 2023, then crashed by 63.03% to $17.3 million in 2024, then skyrocketed by 160.76% to $45.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $45.0 million in Q4 2025, $43.4 million in Q3 2025, and $17.0 million in Q2 2025.